Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening
- PMID: 20449660
- DOI: 10.1007/s10545-010-9090-x
Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening
Abstract
The different long-chain fatty acid oxidation defects present with similar heterogeneous clinical phenotypes of different severity. Organs mainly affected comprise the heart, liver, and skeletal muscles. All symptoms are reversible with sufficient energy supply. In some long-chain fatty acid oxidation defects, disease-specific symptoms occur. Only in disorders of the mitochondrial trifunctional protein (TFP) complex, including long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase (LCHAD) deficiency, neuropathy and retinopathy develop that are progressive and irreversible despite current treatment measures. In most long-chain fatty acid oxidation defects, no clear genotype-phenotype correlation exists due to molecular heterogeneity. However, some isolated mutations have been identified to be associated with only mild phenotypes, e.g., the V243A mutation in very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. LCHAD deficiency is due to the prevalent homozygous 1528G>C mutation and presents with heterogeneous clinical phenotypes, suggesting the importance of other environmental and genetic factors. For some disorders, it was shown that residual enzyme activity measured in fibroblasts or lymphocytes correlated with severity of clinical phenotype. Implementation of newborn screening has significantly reduced morbidity and mortality of long-chain fatty acid oxidation defects. However, the severest forms of TFP deficiency are still highly associated with neonatal death. Newborn screening also identifies a great number of mildly affected patients who may never develop clinical symptoms throughout life. However, later-onset exercise-induced myopathic symptoms remain characteristic clinical features of long-chain fatty acid oxidation defects. Disease prevalence has increased with newborn screening.
Similar articles
-
Fatty acid oxidation disorders: outcome and long-term prognosis.J Inherit Metab Dis. 2010 Oct;33(5):501-6. doi: 10.1007/s10545-009-9001-1. Epub 2010 Jan 5. J Inherit Metab Dis. 2010. PMID: 20049534 Review.
-
Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.J Inherit Metab Dis. 2010 Oct;33(5):521-6. doi: 10.1007/s10545-010-9076-8. Epub 2010 Apr 7. J Inherit Metab Dis. 2010. PMID: 20373143 Review.
-
Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.J Inherit Metab Dis. 2010 Oct;33(5):539-46. doi: 10.1007/s10545-010-9121-7. Epub 2010 Jun 8. J Inherit Metab Dis. 2010. PMID: 20532823 Free PMC article. Review.
-
Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.J Inherit Metab Dis. 2010 Oct;33(5):495-500. doi: 10.1007/s10545-009-9000-2. Epub 2010 Jan 12. J Inherit Metab Dis. 2010. PMID: 20066495 Review.
-
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.J Inherit Metab Dis. 2010 Oct;33(5):555-61. doi: 10.1007/s10545-010-9188-1. Epub 2010 Sep 10. J Inherit Metab Dis. 2010. PMID: 20830526 Review.
Cited by
-
Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.J Hum Genet. 2019 Feb;64(2):73-85. doi: 10.1038/s10038-018-0527-7. Epub 2018 Nov 6. J Hum Genet. 2019. PMID: 30401918 Review.
-
Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders.Genet Med. 2021 May;23(5):816-829. doi: 10.1038/s41436-020-01070-0. Epub 2021 Jan 25. Genet Med. 2021. PMID: 33495527 Free PMC article. Review.
-
Clinical manifestations and management of fatty acid oxidation disorders.Rev Endocr Metab Disord. 2020 Dec;21(4):479-493. doi: 10.1007/s11154-020-09568-3. Rev Endocr Metab Disord. 2020. PMID: 32654032 Free PMC article. Review.
-
Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders.Cell Mol Neurobiol. 2022 Apr;42(3):521-532. doi: 10.1007/s10571-020-00955-7. Epub 2020 Sep 2. Cell Mol Neurobiol. 2022. PMID: 32876899 Free PMC article. Review.
-
Characterization of exonic variants of uncertain significance in very long-chain acyl-CoA dehydrogenase identified through newborn screening.J Inherit Metab Dis. 2022 May;45(3):529-540. doi: 10.1002/jimd.12492. Epub 2022 Mar 11. J Inherit Metab Dis. 2022. PMID: 35218577 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous